Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.23736/S1824-4785.24.03578-7 | DOI Listing |
ArXiv
November 2024
Department of Radiation Oncology, University of Kansas Medical Center, USA.
Objective: Proton spot-scanning arc therapy (ARC) is an emerging modality that can improve the high-dose conformity to targets compared with standard intensity-modulated proton therapy (IMPT). However, the efficient treatment delivery of ARC is challenging due to the required frequent energy changes during the continuous gantry rotation. This work proposes a novel method that delivers a multiple IMPT (multi-IMPT) plan that is equivalent to ARC in terms of biologically effective dose (BED).
View Article and Find Full Text PDFBiosensors (Basel)
October 2024
Department of Pharmaceutical Engineering, Soonchunhyang University, Asan 31538, Republic of Korea.
In this paper, we present a sensitive and highly reproducible fluorescence immunosensor for detecting PSA in human serum. A unique feature of this study is that it uses creatively designed paddle screw-type devices and their custom-made rotating system for PSA immunoassay. The paddle screw devices were designed to maximize the surface-to-volume ratio over which the immunoassay reaction could occur to improve detection sensitivity.
View Article and Find Full Text PDFMed Phys
October 2024
Image X Institute, Sydney School of Health Sciences, The University of Sydney, Sydney, Australia.
Background: Patients with locally advanced prostate cancer require the prostate and pelvic lymph nodes to be irradiated simultaneously during radiation therapy treatment. However, relative motion between treatment targets decreases dosimetric conformity. Current treatment methods mitigate this error by having large treatment margins and often prioritize the prostate at patient setup at the cost of lymph node coverage.
View Article and Find Full Text PDFCancer Res Commun
November 2024
Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.
Non-Hispanic Black patients diagnosed with prostate cancer between 2014 and 2019 and treated at a comprehensive cancer center were less likely to use tumor-specific genomic testing compared with non-Hispanic White patients. Disparities in the use of precision oncology technologies should be monitored and addressed to ensure equitable cancer care.
View Article and Find Full Text PDFBMC Urol
October 2024
Ph.D. in Biostatistics, Lecturer in Statistics, ECO College of Insurance, Allameh Tabataba'i University, Tehran, Iran.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!